Lung Diseases clinical trials at UCLA
5 in progress, 2 open to eligible people
Mosliciguat in PH-ILD
open to eligible people ages 18-80
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Los Angeles, California and other locations
American Lung Association (ALA) Lung Health Cohort
open to eligible people ages 25-35
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Los Angeles, California and other locations
Ralinepag to Improve Treatment Outcomes in PAH Patients
Sorry, in progress, not accepting new patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Los Angeles, California and other locations
Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Sorry, accepting new patients by invitation only
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Los Angeles, California and other locations
Deep Functional Phenotyping of the ALA Lung Health Cohort
Sorry, not currently recruiting here
The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: - the structure of the participants lungs' airways, - the structure of blood vessels in the participants lungs and heart, and - the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure lung function, including: - air movement in the lungs (oscillometry) - lung size (slow vital capacity (SVC) and functional residual capacity (FRC) - gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).
Los Angeles, California and other locations
Our lead scientists for Lung Diseases research studies include Igor Barjaktarevic, MD, PhD Adam J. Brownstein, MD Richard N. Channick, MD.
Last updated: